Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cream trio aims to outshine standard melasma treatment

NCT ID NCT07676994

Disease control Sponsor: Ghurki Trust and Teaching Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study compares a new combination cream (containing isobutylamido-thiazolyl-resorcinol, retinoic acid, and dexamethasone) to the standard Kligman's formula for treating melasma, a common skin condition causing dark patches. The trial enrolls 56 women aged 16–60 who apply the cream nightly for three months. Researchers measure changes in melasma severity and quality of life at 4, 8, and 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
New trio combination (0.1% isobutylamido-thiazolyl-resorcinol, 0.1% retinoic acid, 0.1% dexamethasone)
What this could lead to
If effective, this cream could offer a new option for treating melasma with potentially fewer side effects than standard therapy.
What could go wrong
This is a small, early-phase trial with only 56 participants, so results may not apply to everyone. Possible side effects include redness and burning.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

56 people

The number who actually took part.

Started

May 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female gender * Age range: 16-60 years Exclusion Criteria: * Pregnant females * Lactating mothers * Those taking oral contraceptive pills and phenytoin * Lost to follow up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melasma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Melanosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melasma

Contacts and locations

Locations

  • Ghurki Trust Teaching Hospital

    Lahore, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.